Formulation and Evaluation of Immediate Release Film Coated Tablets of An Anticancer Drug (Dasatinib)

Mohan, Arti; Sangeetha, G.

doi:10.5958/0974-360x.2019.00129.x

Cited by 5 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preparation of Quetiapine Fumarate IR Tablets: Following steps were used in the preparation of Quetiapine Fumarate IR tablets using wet granulation by Glatt-Powder-Coater-Granulator (GPCG) [23]. The formula used in various batches of Quetiapine Fumarate is shown in Table 1.…”

Section: Xrd Studiesmentioning

confidence: 99%

Formulation, Development, and Evaluation of Quetiapine Fumarate Immediate Release Tablets

Boraste¹,

Amrutkar²

2021

Pharmacophore

View full text Add to dashboard Cite

Antipsychotic medications can help control the symptoms of schizophrenia. A variety of scientific and demographic factors show the capability to sway the selection of odd neuroleptic medications. Quetiapine Fumarate is indicated for the treatment of schizophrenia and bipolar disorder. Disintegrating agents are materials that are commonly used in the formulation of tablets and hardshell capsules. Within a short period after administration, drugs should dissolve or disintegrate in the stomach. The most preferred decomposition agent in the making of tablets is starch. The primary purpose of this research was to create a reliable immediate-release tablet formulation of the antipsychotic Quetiapine. Tablets are popular due to their low cost, packaging, and shipping, as well as their greater stability and virtual tamper resistance. Orally administered tablets with a faster disintegration time have a shorter absorption time and higher bioavailability. The goal of the study is to create a stable and physically and chemically compatible generic formulation for treating schizophrenia, as well as a pharmaceutically equivalent instant release tablet for individuals with mental illnesses like schizophrenia and bipolar disorder.

show abstract

Section: Xrd Studiesmentioning

confidence: 99%

Formulation, Development, and Evaluation of Quetiapine Fumarate Immediate Release Tablets

Boraste¹,

Amrutkar²

2021

Pharmacophore

View full text Add to dashboard Cite

show abstract

Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies

et al. 2023

View full text Add to dashboard Cite

Studies on the Quantification of Mutation Resistance to Specific Drug Therapy in Chronic Myeloid Leukemia patients

Darji

Bharadia

2021

RJPT

View full text Add to dashboard Cite

Imatinib is a type of protein tyrosine kinase inhibitor which inhibits the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome i.e. the BCR-ABL tyrosine kinase, abnormality in CML patient. The aim of the study is to assess the response of imatinib in CML patients and to observe resistance to imatinib. Study was performed at Ahmedabad, Gujarat, India. Dose of 400, 600, 800 mg of Imatinib was found to be prescribed to all patients during the study. Comparison of laboratory parameters and PCR data were done after measurement by RT-PCR method. Total 256 patients with CML were enrolled in the study. 196 patients had completed study as per protocol. 38 patients were newly diagnosed whereas 158 patients were already diagnosed with CML. 89.29% (n = 175) of patients achieved complete haematological response, Complete MolR were achieved in n = 41 at 6th months, n = 1 at 12th month and 18th month and no patient was found with none CyR out of 196 patients; no patient were found with minimal CyR at 6th month, 2 patient were at 12th month and 3 patients were at 18th month. Mean PCR value (BCR-ABL/ABL ratio) in patient was found 0.245±1.16 at Day 0, 0.824±1.51 at 6th month, 4.086±9.58 at 12th month and 6.713±11.32 at 18th month visit. In conclusion, it was observed that resistance to imatinib might be developed within an average time of 12 months in the patients due to which survival rate was drastically reduced.

show abstract

Formulation and Evaluation of Immediate Release Film Coated Tablets of An Anticancer Drug (Dasatinib)

Cited by 5 publications

References 0 publications

Formulation, Development, and Evaluation of Quetiapine Fumarate Immediate Release Tablets

Formulation, Development, and Evaluation of Quetiapine Fumarate Immediate Release Tablets

Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies

Studies on the Quantification of Mutation Resistance to Specific Drug Therapy in Chronic Myeloid Leukemia patients

Contact Info

Product

Resources

About